Shield Therapeutics

Digital Marketing And Oral Iron Therapy Will Drive Adoption

AnalystHighTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

17 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

UK£0.23

68.9% undervalued

21 Aug

UK£0.071

107.2%

28.8%

Author's Valuation

UK£0.2

68.9% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

UK£0.2

68.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

27.45%

Pharma revenue growth rate

0.55%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.82%

Calculation

US$47.24m

Earnings '28

8.34x

PE Ratio '28

US$393.81m

Market Cap '28

US$393.81m

Market Cap '28

1.04b

No. shares '28

US$0.38

Share Price '28

US$0.38 Share Price '28

Discounted to 2025 @ 6.82% p.a.

US$0.31

Fair Value '25

US$0.31 Fair Value '25

Converted to GBP @ 0.7433 USD/GBP Exchange Rate

UK£0.23

Fair Value '25